Achieve Life Sciences (NASDAQ:ACHV) Research Coverage Started at Raymond James

Raymond James assumed coverage on shares of Achieve Life Sciences (NASDAQ:ACHV) in a research report report published on Friday morning, Marketbeat.com reports. The brokerage issued a strong-buy rating and a $20.00 price objective on the biopharmaceutical company’s stock.

Separately, Oppenheimer reaffirmed an outperform rating and set a $11.00 target price on shares of Achieve Life Sciences in a research report on Thursday, August 15th.

Achieve Life Sciences Stock Up 7.4 %

Shares of NASDAQ ACHV opened at $4.77 on Friday. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $163.81 million, a PE ratio of -3.70 and a beta of 1.56. The stock’s fifty day simple moving average is $4.52 and its two-hundred day simple moving average is $4.68. Achieve Life Sciences has a 12-month low of $3.03 and a 12-month high of $5.98.

Achieve Life Sciences (NASDAQ:ACHV) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.03). During the same quarter last year, the company earned ($0.43) earnings per share. As a group, analysts expect that Achieve Life Sciences will post -1.01 EPS for the current fiscal year.

Institutional Trading of Achieve Life Sciences

A number of institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in shares of Achieve Life Sciences in the first quarter worth $59,000. The Manufacturers Life Insurance Company acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at $69,000. Renaissance Technologies LLC increased its position in shares of Achieve Life Sciences by 134.2% in the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 14,360 shares during the period. Rhumbline Advisers acquired a new stake in Achieve Life Sciences during the 2nd quarter worth about $197,000. Finally, Bank of New York Mellon Corp acquired a new stake in Achieve Life Sciences during the 2nd quarter worth about $482,000. 33.52% of the stock is currently owned by institutional investors and hedge funds.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.